Aprea Therapeutics, Inc. (APRE) stock
APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.45+0.05 (+11.52%)
Close on Nov 17, 2026Market cap $5.71MP/E –Yield –
Aprea Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Aprea Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.72M, down 30.0% year over year. For fiscal 2025 it was $7.04M, down 24.8% from the year before. The highest annual figure on record is $37.88M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.04M | -24.8% |
| FY2024 | Dec 31, 2024 | $9.36M | +22.8% |
| FY2023 | Dec 31, 2023 | $7.63M | -53.5% |
| FY2022 | Dec 31, 2022 | $16.40M | -31.4% |
| FY2021 | Dec 31, 2021 | $23.90M | -36.9% |
| FY2020 | Dec 31, 2020 | $37.88M | +80.8% |
| FY2019 | Dec 31, 2019 | $20.95M | +47.6% |
| FY2018 | Dec 31, 2018 | $14.19M | +6.0% |
| FY2017 | Dec 31, 2017 | $13.39M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.46M | +28.8% |
| Q1 FY2026 | Mar 31, 2026 | $1.61M | -35.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.01M | -57.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.64M | -42.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.91M | -25.2% |
| Q1 FY2025 | Mar 31, 2025 | $2.48M | +55.2% |
| Q4 FY2024 | Dec 31, 2024 | $2.36M | +15.3% |
| Q3 FY2024 | Sep 30, 2024 | $2.85M | +34.1% |
| Q2 FY2024 | Jun 30, 2024 | $2.56M | +16.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.60M | +27.4% |
| Q4 FY2023 | Dec 31, 2023 | $2.05M | +285.0% |
| Q3 FY2023 | Sep 30, 2023 | $2.12M | +89.9% |
| Q2 FY2023 | Jun 30, 2023 | $2.20M | -67.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.26M | -69.3% |
| Q4 FY2022 | Dec 31, 2022 | $531.41K | -88.1% |
| Q3 FY2022 | Sep 30, 2022 | $1.12M | -81.4% |
| Q2 FY2022 | Jun 30, 2022 | $6.81M | +2.4% |
| Q1 FY2022 | Mar 31, 2022 | $4.09M | -39.5% |
| Q4 FY2021 | Dec 31, 2021 | $4.46M | -52.2% |
| Q3 FY2021 | Sep 30, 2021 | $6.02M | -31.3% |
| Q2 FY2021 | Jun 30, 2021 | $6.65M | -37.8% |
| Q1 FY2021 | Mar 31, 2021 | $6.76M | -25.6% |
| Q4 FY2020 | Dec 31, 2020 | $9.33M | +16.0% |
| Q3 FY2020 | Sep 30, 2020 | $8.76M | +78.4% |
| Q2 FY2020 | Jun 30, 2020 | $10.69M | +147.6% |
| Q1 FY2020 | Mar 31, 2020 | $9.10M | +147.3% |
| Q4 FY2019 | Dec 31, 2019 | $8.04M | +83.0% |
| Q3 FY2019 | Sep 30, 2019 | $4.91M | +112.8% |
| Q2 FY2019 | Jun 30, 2019 | $4.32M | – |
| Q1 FY2019 | Mar 31, 2019 | $3.68M | – |
| Q4 FY2018 | Dec 31, 2018 | $4.39M | – |
| Q3 FY2018 | Sep 30, 2018 | $2.31M | – |
See a number that looks wrong?